In a patient with acute coronary syndrome awaiting transfer to the catheterization lab, which single agent is typically administered?

In a patient with acute coronary syndrome awaiting transfer to the catheterization lab, which single agent is typically administered?

• A. Plavix
• B. Aspirin
• C. Heparin
• D. Morphine

Answer: (A)

Early antiplatelet therapy is essential in acute coronary syndrome because the immediate danger is ongoing platelet-driven thrombosis at a ruptured plaque. Aspirin works best as a single agent at this moment because it rapidly and irreversibly inhibits cyclooxygenase-1 in platelets, preventing thromboxane A2 formation and thus stopping further platelet aggregation. The quick onset, proven mortality benefit, and wide availability make a chewable aspirin dose the standard initial step while the patient is awaiting transfer to the catheterization lab. Other options have important roles as adjuncts or in different contexts—plavix is typically added after aspirin or used around PCI; heparin is an anticoagulant used during procedures or in specific protocols; morphine treats pain but does not address the thrombotic process and is not the primary pre-PCI therapy.

Early antiplatelet therapy is essential in acute coronary syndrome because the immediate danger is ongoing platelet-driven thrombosis at a ruptured plaque. Aspirin works best as a single agent at this moment because it rapidly and irreversibly inhibits cyclooxygenase-1 in platelets, preventing thromboxane A2 formation and thus stopping further platelet aggregation. The quick onset, proven mortality benefit, and wide availability make a chewable aspirin dose the standard initial step while the patient is awaiting transfer to the catheterization lab. Other options have important roles as adjuncts or in different contexts—plavix is typically added after aspirin or used around PCI; heparin is an anticoagulant used during procedures or in specific protocols; morphine treats pain but does not address the thrombotic process and is not the primary pre-PCI therapy.